Our research at the Centre for Regenerative Medicine and Devices is person-centred. We listen to the opinions of the public, the patients and their relatives.
The centre explores three different routes towards future tangible impact and engagement:
- Commercial and clinical impact
- Educational impact
- Societal engagement
Commercial and clinical impact
Members of the centre develop medicines and devices for commercial use. Together with university colleagues in business and marketing, they conduct negotiations for end users and industrial partners to use the innovations and developments from their research, including intellectual property rights related to biomaterials.
Soybean-based Biomaterials Exploitation Process: The University of Brighton has agreed the exclusive licensing of two patents protecting IP on soybean-based biomaterials to Brighton Wound Care Ltd (BWC). The IP originates from a ground-breaking innovation by members of the CRMD. Since then BWC has made significant progresses in exploiting the technology for the commercialisation of soybean-based wound dressings. The exploitation was supported by venture capital and led to the establishment of a new R&D and manufacturing company, Meilian Medical Technology, Suzhou, China.
Meilian Medical Technology has optimised the manufacturing of the soybean-based biomaterial formulations most suitable as wound dressings. This includes a scale-up pilot plant for the extraction of relevant compounds from soya
The results from pre-clinical studies so far collected on a number of models show excellent healing of wounds and burns. A report of the data collected so far has been issued by an independent clinical expert and it has been made available to BWC.
During the reporting period, Meilian Medical Technology has employed 7 members of the personnel. Professor Santin regularly visits the company’s premises to discuss technical and exploitation plans with the company that aims to launch their products on the market in 2019.
Tissue Click: Technology and expertise from the Centre for Regenerative Medicine and Devices has led to the establishment of Tissue Click Ltd, a company with a mission in producing biomimetic biomaterials substrates for the controlled culture of different types of cells. The product, PhenoDrive is now available on the market and attracting the interest of researchers worldwide. The company employs personnel previously at the University of Brighton as either researchers or as PhD students.